Drug
Meribatinib clinical trials
Also written TGRX-678.
- studies test it
- 6
- open now
- 3
- in phase 3
- 1
- first study started
- 2021
Keep track of what changes. Save the Meribatinib studies recruiting or about to start, and get an email each week — studies that open, close, add sites or post results.
Watch these studiesHow studies write it
Studies that test it under each name
Development codes
Studies by the year they started
6 studies that test it; most in 2024 (3)
| Year | Studies |
|---|---|
| 2021 | 1 |
| 2024 | 3 |
| 2025 | 1 |
| 2026 | 1 |
By phase
A phase 1/2 study counts in both.
- Phase 1
- 4
- Phase 2
- 1
- Phase 3
- 1
What it is tested for
Each study’s main condition, where its own words name it.
Who runs them
Industry 6 · Other 0
Shenzhen TargetRx, Inc. (3) · Shenzhen TargetRx Co., Ltd. (3)
Studies
Open first, then newest update. How each study uses Meribatinib is read from its arms, and is right about nine times in ten.
Testing it · 6
- TGRX-678 US Phase I for Chronic Myelogenous Leukemia PatientsRecruitingPhase 1Shenzhen TargetRx Co., Ltd.NCT06088888Written as TGRX-678
- TGRX-678 Chinese Phase III in Chronic Myelogenous Leukemia (CML) PatientsNot yet recruitingPhase 3Shenzhen TargetRx Co., Ltd.NCT07489755Written as TGRX-678
- TGRX-678 Chinese Phase II in Chronic Myelogenous Leukemia (CML) PatientsRecruitingPhase 2Shenzhen TargetRx, Inc.NCT06453902Written as TGRX-678
- TGRX-678 Pharmacokinetic Mass BalanceCompletedPhase 1Shenzhen TargetRx Co., Ltd.NCT06986772Written as [14C]TGRX-678
- TGRX-678 Phase I Oral Pharmacokinetic StudyCompletedPhase 1Shenzhen TargetRx, Inc.NCT06697899Written as TGRX-678
- TGRX-678 Chinese Phase I in Chronic Myelogenous Leukemia (CML) PatientsActive, not recruitingPhase 1Shenzhen TargetRx, Inc.NCT05434312Written as TGRX-678